Actively Recruiting
Evaluating Intravenous and Subcutaneous BI 3032950 Treatment for Adults With Moderate to Severe Ulcerative Colitis
Led by Boehringer Ingelheim · Updated on 2026-08-21
80
Participants Needed
41
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BI 3032950 as a treatment for adults aged 18 to 80 with moderate to severe ulcerative colitis who have not had success with previous biologic or targeted therapies or who stopped such treatments. The study aims to assess whether BI 3032950 can help improve symptoms and achieve clinical remission in this patient group. The study has two parts. In Part A, participants receive BI 3032950 through an infusion into a vein every 4 weeks for 12 weeks. After this, participants move to Part B, where they receive BI 3032950 as injections under the skin every 4 weeks for up to 2 years if they show clinical response. All participants receive the study drug without placebo comparison. Participants visit their doctors every 4 weeks for assessments including symptom checks, blood and stool sample collection, and endoscopies to examine the colon. Researchers monitor clinical remission using the modified Mayo Score and check for any side effects. The study involves regular health evaluations up to 2 years to assess the treatments safety and effectiveness.
CONDITIONS
Brief Title
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here